Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

被引：0
|
作者：
Heinrich, Michael C.
von Mehren, Margaret
Demetri, George D.
Fletcher, Jonathan A.
Sun, Jichao G.
Kerstein, David
Conlan, Maureen G.
George, Suzanne
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA
[3] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[5] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[6] Ariad Pharmaceut Inc, Cambridge, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10535
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy
    Van den Abbeele, A. D.
    Yap, J. T.
    Grayzel, D. S.
    Walker, J.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST)
    Heinrich, Michael C.
    Hodgson, J. Graeme
    von Mehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao G.
    Pritchard, Justin R.
    Zhang, Sen
    Rivera, Victor M.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib
    Cho, H.
    Ryu, M-H.
    Kim, B. J.
    Park, Y.
    Na, Y-S.
    Ma, J.
    Beck, M. Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors
    Moore, Kathleen N.
    Jones, Suzanne Fields
    Kurkjian, Carla
    Arkenau, Hendrik-Tobias
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    McMeekin, D. Scott
    Gibbons, Jay
    Harrow, Kimberly
    Liang, Chris
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
  • [26] A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
    George, S.
    von Mehren, M.
    Heinrich, M. C.
    Wang, Q.
    Corless, C. L.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    Choy, E.
    Tap, W. D.
    Manola, J.
    Yap, J. T.
    Van den Abbeele, A. D.
    Solomon, S.
    Fletcher, J. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM RESULTS OF A PHASE 2 STUDY
    Jones, J. A.
    Andritsos, L.
    Ravandi, F.
    Kreitman, R. J.
    Schiffer, C.
    Call, T.
    Lozanski, G.
    Sexton, J.
    Harris, P.
    Grever, M. R.
    HAEMATOLOGICA, 2015, 100 : 313 - 313
  • [28] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [29] Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).
    Li, Jian
    Chi, Ping
    Kang, Yoon-Koo
    Cao, Hui
    George, Suzanne
    Zhang, Jun
    Zhang, Jian
    Hu, Kang
    Zhang, Lijia
    Xu, Yanhua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
    Li, Jian
    Gong, Jifang
    Wang, Xicheng
    Li, Jie
    Li, Yan
    Qi, Changsong
    Shen, Lin
    Ren, Wenxiao
    Zhao, Wanqi
    Wang, Yedong
    Hu, Jin
    Ren, Chunli
    Song, Wenjie
    Yang, Jianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345